VBI Vaccines (VBIV) Presents at Rodman & Renshaw Conference

VBI Vaccines, Inc. (NASDAQ:VBIV) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s lead eVLP asset is a prophylactic Cytomegalovirus (“CMV”) vaccine. The company has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and phase I trials. VBI’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. For more information, visit the company’s website at www.vbivaccines.com